dc.contributor
Institut Català de la Salut
dc.contributor
[O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James’s and Leeds Teaching Hospitals Trust, Leeds, UK. [Goldstein LJ] Fox Chase Cancer Center, Philadelphia, PA, USA. [Alexis K, Xie R] Eisai Inc., Woodclif Lake, NJ, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
O’Shaughnessy, Joyce
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Twelves, Chris
dc.contributor.author
Goldstein, Lori J.
dc.contributor.author
Alexis, Karenza
dc.contributor.author
Xie, Ran
dc.date.accessioned
2025-10-25T05:39:29Z
dc.date.available
2025-10-25T05:39:29Z
dc.date.issued
2021-09-03T10:51:26Z
dc.date.issued
2021-09-03T10:51:26Z
dc.date.issued
2020-07-08
dc.identifier
O’Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep. 2020 Jul 8;10:11203.
dc.identifier
https://hdl.handle.net/11351/6269
dc.identifier
10.1038/s41598-020-66980-0
dc.identifier
000548300100011
dc.identifier.uri
http://hdl.handle.net/11351/6269
dc.description.abstract
Càncer de mama; Marcadors predictius; Pronòstic
dc.description.abstract
Cáncer de mama; Marcadores predictivos; Pronóstico
dc.description.abstract
Breast cancer; Predictive markers; Prognosis
dc.description.abstract
Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.
dc.description.abstract
This study was funded by Eisai Inc., Woodcliff Lake, NJ. Medical writing support was provided by Jeffrey Bratz, PhD, Oxford PharmaGenesis, Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Nature Research
dc.relation
Scientific Reports;10
dc.relation
https://doi.org/10.1038/s41598-020-66980-0
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.title
Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
